IN8bio stock (US45332Y1001): Clinical-stage biotech focused on gamma-delta T cell therapies

IN8bio develops cellular immunotherapies targeting gamma-delta T cells for cancer treatment. US investors follow its pipeline progress amid biotech sector volatility.

IN8bio advances its clinical-stage pipeline of gamma-delta T cell therapies designed to treat solid tumors and hematologic malignancies. The company, listed on Nasdaq, focuses on engineered T cells that leverage the innate anti-tumor properties of gamma-delta T cells, offering potential advantages over traditional alpha-beta T cell therapies.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IN8bio Inc
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology therapeutics
• Key revenue drivers: Clinical milestones, partnerships
• Home exchange/listing venue: Nasdaq (INAB)
• Trading currency: USD

IN8bio: core business model

IN8bio's platform centers on DeltEx D-?? T cells, which are expanded and engineered ex vivo for enhanced persistence and tumor-killing capability. Unlike conventional CAR-T therapies reliant on alpha-beta T cells, gamma-delta T cells recognize stress signals on tumor cells independently of MHC presentation, potentially reducing immune evasion risks. The company's lead program, INB-400, targets glioblastoma, a highly aggressive brain cancer with limited treatment options.

IN8bio operates as a clinical-stage biotech with no approved products, relying on equity financing and grants to fund R&D. Its business model emphasizes rapid iteration through Phase 1/2 trials to generate proof-of-concept data, positioning for partnerships or buyouts by larger pharma players interested in next-generation cell therapies.

Main revenue and product drivers for IN8bio

Pipeline progress drives value, with INB-400 in a Phase 1 trial for glioblastoma showing initial safety data as reported in company updates. INB-200, targeting hematologic cancers, and preclinical assets like INB-300 for solid tumors represent future catalysts. Milestone payments from potential collaborations and FDA designations, such as orphan drug status, bolster the pipeline's appeal.

IN8bio's revenue remains pre-commercial, with cash runway extending into 2026 based on Q4 2025 financials published in early 2026. R&D expenses focus on manufacturing scale-up and combination therapies with checkpoint inhibitors, critical for US investors tracking biotech cash burn rates.

Industry trends and competitive position

The cell therapy sector sees gamma-delta T cells as a promising alternative amid challenges with CAR-T manufacturing and toxicity. Competitors like Gadeta and Lava Therapeutics pursue similar modalities, but IN8bio differentiates via its allogeneic approach and glioblastoma focus, a niche with high unmet need. US market exposure comes via Nasdaq listing and trials at leading cancer centers.

Why IN8bio matters for US investors

Listed on Nasdaq, IN8bio offers US retail investors access to innovative oncology plays without international trading hurdles. Its pipeline addresses US-prevalent cancers like glioblastoma, with potential FDA fast-track paths enhancing appeal amid a biotech rally driven by M&A activity.

Conclusion

IN8bio represents a high-risk, high-reward profile in cellular immunotherapy, with gamma-delta T cells offering novel tumor-targeting mechanisms. Clinical data readouts and funding events will shape near-term trajectory. Investors monitor pipeline advancements alongside broader biotech sentiment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.